

Yuan Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8813667/publications.pdf>

Version: 2024-02-01

83
papers

3,713
citations

147801

31
h-index

133252

59
g-index

84
all docs

84
docs citations

84
times ranked

3994
citing authors

#	ARTICLE	IF	CITATIONS
1	Coordination of rigidity modulation and targeting ligand modification on orally-delivered nanoparticles for the treatment of liver fibrosis. <i>Journal of Controlled Release</i> , 2022, 341, 215-226.	9.9	15
2	Exocytosis blockade of endoplasmic reticulum-targeted nanoparticle enhances immunotherapy. <i>Nano Today</i> , 2022, 42, 101356.	11.9	14
3	Co-delivery of mitochondrial targeted lonidamine and PIN1 inhibitor ATRA by nanoparticulate systems for synergistic metastasis suppression. <i>Nano Research</i> , 2022, 15, 3376-3386.	10.4	6
4	Redirecting Chemotherapeutics to the Endoplasmic Reticulum Increases Tumor Immunogenicity and Potentiates Anti-PD-L1 Therapy. <i>Small</i> , 2022, 18, e2104591.	10.0	23
5	Combination of mitochondria impairment and inflammation blockade to combat metastasis. <i>Journal of Controlled Release</i> , 2022, 341, 753-768.	9.9	5
6	A liposome-based combination strategy using doxorubicin and a PI3K inhibitor efficiently inhibits pre-metastatic initiation by acting on both tumor cells and tumor-associated macrophages. <i>Nanoscale</i> , 2022, 14, 4573-4587.	5.6	4
7	Immunogenic hydrogel toolkit disturbing residual tumor "seeds" and pre-metastatic "soil" for inhibition of postoperative tumor recurrence and metastasis. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3383-3397.	12.0	21
8	Trauma-Responsive Scaffold Synchronizing Oncolysis Immunization and Inflammation Alleviation for Post-Operative Suppression of Cancer Metastasis. <i>ACS Nano</i> , 2022, 16, 6064-6079.	14.6	11
9	Stimuli-responsive nano vehicle enhances cancer immunotherapy by coordinating mitochondria-targeted immunogenic cell death and PD-L1 blockade. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2533-2549.	12.0	22
10	Spatially targeting of tumor-associated macrophages and cancer cells for suppression of spontaneously metastatic tumor. <i>Nano Research</i> , 2022, 15, 3446-3457.	10.4	1
11	Targeted Inhibition of Tumor Inflammation and Tumor-Platelet Crosstalk by Nanoparticle-Mediated Drug Delivery Mitigates Cancer Metastasis. <i>ACS Nano</i> , 2022, 16, 50-67.	14.6	29
12	Milk-derived exosomes exhibit versatile effects for improved oral drug delivery. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2029-2042.	12.0	35
13	Split bullets loaded nanoparticles for amplified immunotherapy. <i>Journal of Controlled Release</i> , 2022, 347, 199-210.	9.9	9
14	Complying with the physiological functions of Golgi apparatus for secretory exocytosis facilitated oral absorption of protein drugs. <i>Journal of Materials Chemistry B</i> , 2021, 9, 1707-1718.	5.8	6
15	Angiopep-2-functionalized nanoparticles enhance transport of protein drugs across intestinal epithelia by self-regulation of targeted receptors. <i>Biomaterials Science</i> , 2021, 9, 2903-2916.	5.4	9
16	Sequentially Targeting Cancer-Associated Fibroblast and Mitochondria Alleviates Tumor Hypoxia and Inhibits Cancer Metastasis by Preventing "Soil" Formation and "Seed" Dissemination. <i>Advanced Functional Materials</i> , 2021, 31, 2010283.	14.9	18
17	Active Targeting Nanoparticle Self-Assembled from Cisplatin-Palboiciclib Amphiphiles Ensures Optimal Drug Ratio for Combinatorial Chemotherapy. <i>Advanced Therapeutics</i> , 2021, 4, 2000261.	3.2	8
18	Stimuli-Responsive Nanoparticles Combining Photodynamic Therapy and Mitochondria Disruption Suppressed Tumor Metastasis. <i>Advanced Materials Interfaces</i> , 2021, 8, 2002200.	3.7	10

#	ARTICLE	IF	CITATIONS
19	Improving anti-PD-L1 therapy in triple negative breast cancer by polymer-enhanced immunogenic cell death and CXCR4 blockade. <i>Journal of Controlled Release</i> , 2021, 334, 248-262.	9.9	22
20	Investigation of FcRn-Mediated Transepithelial Mechanisms for Oral Nanoparticle Delivery Systems. <i>Advanced Therapeutics</i> , 2021, 4, 2100145.	3.2	5
21	Concurrent impairment of nucleus and mitochondria for synergistic inhibition of cancer metastasis. <i>International Journal of Pharmaceutics</i> , 2021, 608, 121077.	5.2	9
22	Combination of mitochondria targeting doxorubicin with Bcl-2 function-converting peptide NuBCP-9 for synergistic breast cancer metastasis inhibition. <i>Journal of Materials Chemistry B</i> , 2021, 9, 1336-1350.	5.8	5
23	Targeting the Opening of Mitochondrial Permeability Transition Pores Potentiates Nanoparticle Drug Delivery and Mitigates Cancer Metastasis. <i>Advanced Science</i> , 2021, 8, 2002834.	11.2	25
24	Restoration and Enhancement of Immunogenic Cell Death of Cisplatin by Coadministration with Digoxin and Conjugation to HPMA Copolymer. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 1606-1616.	8.0	30
25	Tailored elasticity combined with biomimetic surface promotes nanoparticle transcytosis to overcome mucosal epithelial barrier. <i>Biomaterials</i> , 2020, 262, 120323.	11.4	45
26	Mitochondrial targeted strategies and their application for cancer and other diseases treatment. <i>Journal of Pharmaceutical Investigation</i> , 2020, 50, 271-293.	5.3	34
27	Enhanced nuclear delivery of H1-S6A, F8A peptide by NrTP6-modified polymeric platform. <i>International Journal of Pharmaceutics</i> , 2020, 580, 119224.	5.2	3
28	A novel mitochondrial targeted hybrid peptide modified HPMA copolymers for breast cancer metastasis suppression. <i>Journal of Controlled Release</i> , 2020, 325, 38-51.	9.9	38
29	Nanoparticles with surface features of dendritic oligopeptides as potential oral drug delivery systems. <i>Journal of Materials Chemistry B</i> , 2020, 8, 2636-2649.	5.8	13
30	Promoting apical-to-basolateral unidirectional transport of nanoformulations by manipulating the nutrient-absorption pathway. <i>Journal of Controlled Release</i> , 2020, 323, 151-160.	9.9	13
31	Enhanced Reactive Oxygen Species Generation by Mitochondria Targeting of Anticancer Drug To Overcome Tumor Multidrug Resistance. <i>Biomacromolecules</i> , 2019, 20, 3755-3766.	5.4	34
32	Enhanced intracellular and intranuclear drug delivery mediated by biomimetic peptide SVS-1 for anticancer therapy. <i>International Journal of Pharmaceutics</i> , 2019, 570, 118668.	5.2	9
33	Overcoming chemotherapy resistance via simultaneous drug-efflux circumvention and mitochondrial targeting. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 615-625.	12.0	61
34	Biomimetic Viruslike and Charge Reversible Nanoparticles to Sequentially Overcome Mucus and Epithelial Barriers for Oral Insulin Delivery. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 9916-9928.	8.0	113
35	Novel Solid Lipid Nanoparticle with Endosomal Escape Function for Oral Delivery of Insulin. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 9315-9324.	8.0	93
36	Programmed drug delivery system based on optimized size decrease and hydrophilicity/hydrophobicity transformation for enhanced hepatocellular carcinoma therapy of doxorubicin. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 1111-1122.	3.3	18

#	ARTICLE	IF	CITATIONS
37	Iron-mimic peptide converts transferrin from foe to friend for orally targeting insulin delivery. <i>Journal of Materials Chemistry B</i> , 2018, 6, 593-601.	5.8	27
38	The combination of endolysosomal escape and basolateral stimulation to overcome the difficulties of "easy uptake hard transcytosis" of ligand-modified nanoparticles in oral drug delivery. <i>Nanoscale</i> , 2018, 10, 1494-1507.	5.6	44
39	Engineering nanomaterials to overcome the mucosal barrier by modulating surface properties. <i>Advanced Drug Delivery Reviews</i> , 2018, 124, 150-163.	13.7	120
40	Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response strategies. <i>International Journal of Pharmaceutics</i> , 2018, 536, 450-458.	5.2	11
41	Mitochondria-targeting and cell-penetrating peptides-co-modified HPMA copolymers for enhancing therapeutic efficacy of α -tocopheryl succinate. <i>Journal of Materials Chemistry B</i> , 2018, 6, 7674-7683.	5.8	16
42	Enhanced cellular uptake by non-endocytic pathway for tumor therapy. <i>Journal of Materials Chemistry B</i> , 2018, 6, 7411-7419.	5.8	2
43	Improved anticancer efficacy of doxorubicin mediated by human-derived cell-penetrating peptide dNP2. <i>International Journal of Pharmaceutics</i> , 2018, 551, 14-22.	5.2	18
44	Multifunctional Nanoparticles Enable Efficient Oral Delivery of Biomacromolecules via Improving Payload Stability and Regulating the Transcytosis Pathway. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 34039-34049.	8.0	47
45	Transport Mechanisms of Butyrate Modified Nanoparticles: Insight into "Easy Entry, Hard Transcytosis" of Active Targeting System in Oral Administration. <i>Molecular Pharmaceutics</i> , 2018, 15, 4273-4283.	4.6	27
46	Two birds, one stone: dual targeting of the cancer cell surface and subcellular mitochondria by the galectin-3-binding peptide G3-C12. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 806-822.	6.1	32
47	A strategy for developing effective orally-delivered nanoparticles through modulation of the surface "hydrophilicity/hydrophobicity balance". <i>Journal of Materials Chemistry B</i> , 2017, 5, 1302-1314.	5.8	18
48	Lipid nanovehicles with adjustable surface properties for overcoming multiple barriers simultaneously in oral administration. <i>International Journal of Pharmaceutics</i> , 2017, 520, 216-227.	5.2	24
49	Dual-sensitive and biodegradable core-crosslinked HPMA copolymer "doxorubicin conjugate-based nanoparticles for cancer therapy. <i>Polymer Chemistry</i> , 2017, 8, 2370-2380.	3.9	25
50	Subcellular co-delivery of two different site-oriented payloads for tumor therapy. <i>Nanoscale</i> , 2017, 9, 1547-1558.	5.6	17
51	Systematic evaluation of the toxicity and biodistribution of virus mimicking mucus-penetrating DLPC-NPs as oral drug delivery system. <i>International Journal of Pharmaceutics</i> , 2017, 530, 89-98.	5.2	21
52	Bioinspired butyrate-functionalized nanovehicles for targeted oral delivery of biomacromolecular drugs. <i>Journal of Controlled Release</i> , 2017, 262, 273-283.	9.9	58
53	Charge-Reversible Multifunctional HPMA Copolymers for Mitochondrial Targeting. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 27563-27574.	8.0	27
54	Enhanced nuclear delivery of anti-cancer drugs using micelles containing releasable membrane fusion peptide and nuclear-targeting retinoic acid. <i>Journal of Materials Chemistry B</i> , 2017, 5, 7175-7185.	5.8	17

#	ARTICLE	IF	CITATIONS
55	A pH-responsive sequential-disassembly nanohybrid for mitochondrial targeting. <i>Nanoscale</i> , 2017, 9, 314-325.	5.6	37
56	Polymeric Nanoparticles Amenable to Simultaneous Installation of Exterior Targeting and Interior Therapeutic Proteins. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 3309-3312.	13.8	121
57	Dual-pH responsive micelle platform for co-delivery of axitinib and doxorubicin. <i>International Journal of Pharmaceutics</i> , 2016, 507, 50-60.	5.2	29
58	Time-staggered delivery of docetaxel and H1-S6A,F8A peptide for sequential dual-strike chemotherapy through tumor priming and nuclear targeting. <i>Journal of Controlled Release</i> , 2016, 232, 62-74.	9.9	31
59	Dual Stimuli-Responsive Hybrid Polymeric Nanoparticles Self-Assembled from POSS-Based Starlike Copolymer-Drug Conjugates for Efficient Intracellular Delivery of Hydrophobic Drugs. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 13251-13261.	8.0	51
60	Enhanced Oral Delivery of Protein Drugs Using Zwitterion-Functionalized Nanoparticles to Overcome both the Diffusion and Absorption Barriers. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 25444-25453.	8.0	127
61	Direct Cytoplasmic Delivery and Nuclear Targeting Delivery of HPMA-MT Conjugates in a Microtubules Dependent Fashion. <i>Molecular Pharmaceutics</i> , 2016, 13, 3069-3079.	4.6	5
62	Core-shell stability of nanoparticles plays an important role for overcoming the intestinal mucus and epithelium barrier. <i>Journal of Materials Chemistry B</i> , 2016, 4, 5831-5841.	5.8	22
63	Sub-50 nm Nanoparticles with Biomimetic Surfaces to Sequentially Overcome the Mucosal Diffusion Barrier and the Epithelial Absorption Barrier. <i>Advanced Functional Materials</i> , 2016, 26, 2728-2738.	14.9	88
64	The transport mechanism of integrin $\alpha_5\beta_3$ receptor targeting nanoparticles in Caco-2 cells. <i>International Journal of Pharmaceutics</i> , 2016, 500, 42-53.	5.2	38
65	An in vitro investigation of a detachable fork-like structure as efficient nuclear-targeted sub-unit in A2780 cell cultures. <i>International Journal of Pharmaceutics</i> , 2016, 500, 100-109.	5.2	8
66	Efficient mucus permeation and tight junction opening by dissociable mucus-inert agent coated trimethyl chitosan nanoparticles for oral insulin delivery. <i>Journal of Controlled Release</i> , 2016, 222, 67-77.	9.9	210
67	A novel ligand conjugated nanoparticles for oral insulin delivery. <i>Drug Delivery</i> , 2016, 23, 2015-2025.	5.7	37
68	Exendin-4 Loaded Nanoparticles with a Lipid Shell and Aqueous Core Containing Micelles for Enhanced Intestinal Absorption. <i>Journal of Biomedical Nanotechnology</i> , 2015, 11, 865-876.	1.1	25
69	Multistage Nanovehicle Delivery System Based on Stepwise Size Reduction and Charge Reversal for Programmed Nuclear Targeting of Systemically Administered Anticancer Drugs. <i>Advanced Functional Materials</i> , 2015, 25, 4101-4113.	14.9	118
70	Goblet cell targeting nanoparticle containing drug-loaded micelle cores for oral delivery of insulin. <i>International Journal of Pharmaceutics</i> , 2015, 496, 993-1005.	5.2	61
71	Overcoming the Diffusion Barrier of Mucus and Absorption Barrier of Epithelium by Self-Assembled Nanoparticles for Oral Delivery of Insulin. <i>ACS Nano</i> , 2015, 9, 2345-2356.	14.6	318
72	The impact of the HPMA polymer structure on the targeting performance of the conjugated hydrophobic ligand. <i>RSC Advances</i> , 2015, 5, 14858-14870.	3.6	8

#	ARTICLE	IF	CITATIONS
73	Improvement of anti-tumor abilities on human non-small cell lung carcinoma by micellization and cross-linking of N-(2-hydroxypropyl) methacrylamide copolymers. <i>Journal of Drug Targeting</i> , 2015, 23, 821-831.	4.4	4
74	A smart polymeric platform for multistage nucleus-targeted anticancer drug delivery. <i>Biomaterials</i> , 2015, 65, 43-55.	11.4	85
75	Polymeric Nanomedicine for Tumor-Targeted Combination Therapy to Elicit Synergistic Genotoxicity against Prostate Cancer. <i>ACS Applied Materials & Interfaces</i> , 2015, 7, 6661-6673.	8.0	58
76	Developments of mucus penetrating nanoparticles. <i>Asian Journal of Pharmaceutical Sciences</i> , 2015, 10, 275-282.	9.1	136
77	G3-C12 Peptide Reverses Galectin-3 from Foe to Friend for Active Targeting Cancer Treatment. <i>Molecular Pharmaceutics</i> , 2015, 12, 4124-4136.	4.6	36
78	Mechanism Study of Cellular Uptake and Tight Junction Opening Mediated by Goblet Cell-Specific Trimethyl Chitosan Nanoparticles. <i>Molecular Pharmaceutics</i> , 2014, 11, 1520-1532.	4.6	107
79	Tumor targeting by pH-sensitive, biodegradable, cross-linked N-(2-hydroxypropyl) methacrylamide copolymer micelles. <i>Biomaterials</i> , 2014, 35, 6622-6635.	11.4	76
80	Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting. <i>Biomaterials</i> , 2014, 35, 5171-5187.	11.4	120
81	Orally delivered salmon calcitonin-loaded solid lipid nanoparticles prepared by micelle double emulsion method via the combined use of different solid lipids. <i>Nanomedicine</i> , 2013, 8, 1085-1100.	3.3	59
82	Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. <i>Biomaterials</i> , 2012, 33, 1573-1582.	11.4	270
83	Treatment of prostate carcinoma with (Galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates. <i>Biomaterials</i> , 2012, 33, 2260-2271.	11.4	59